[
  {
    "ts": null,
    "headline": "U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of TREMFYA® in moderately to severely active ulcerative colitis (UC)",
    "url": "https://finnhub.io/api/news?id=6d6e0dd9f22565b7dc1f5f5ede13f84ba37ac8cfd1ed9ea7a30040293a5f93d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742508720,
      "headline": "U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease",
      "id": 133324562,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous (SC) and intravenous (IV) induction options, for the treatment of adults with moderately to severely active Crohn's disease (CD), a chronic inflammatory condition of the gastrointestinal tract.1 This milestone builds upon the FDA approval of TREMFYA® in moderately to severely active ulcerative colitis (UC)",
      "url": "https://finnhub.io/api/news?id=6d6e0dd9f22565b7dc1f5f5ede13f84ba37ac8cfd1ed9ea7a30040293a5f93d0"
    }
  },
  {
    "ts": null,
    "headline": "Historic Dividend Outperformance",
    "summary": "For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025.",
    "url": "https://finnhub.io/api/news?id=2d815f08f8492faab4f61a45b3fefb9af97f61abf91363de2b42b428d645dad9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742501100,
      "headline": "Historic Dividend Outperformance",
      "id": 133294633,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/157483234/image_157483234.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "For year to date performance, the biggest losers are now mostly growth factors, whereas low volatility and dividend focused ETFs are actually still in the green so far in 2025.",
      "url": "https://finnhub.io/api/news?id=2d815f08f8492faab4f61a45b3fefb9af97f61abf91363de2b42b428d645dad9"
    }
  },
  {
    "ts": null,
    "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 delet",
    "url": "https://finnhub.io/api/news?id=7e9f1b09c43569634f24161cce89f6ce17b193f3314abf7e268f568f723e131c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742472000,
      "headline": "RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025",
      "id": 133324563,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer Congress (ELCC), including overall survival (OS) results from the Phase 3 MARIPOSA study evaluating RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) versus osimertinib in the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 delet",
      "url": "https://finnhub.io/api/news?id=7e9f1b09c43569634f24161cce89f6ce17b193f3314abf7e268f568f723e131c"
    }
  },
  {
    "ts": null,
    "headline": "Defensive Stocks For Unpredictable Trump Policy",
    "summary": "Navigate market volatility with defensive stocks, bonds, and gold.",
    "url": "https://finnhub.io/api/news?id=3a7f34c516b912e4da5e6ab19d098a97e373f71f94dfa6f751a599d77a1b754c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742469633,
      "headline": "Defensive Stocks For Unpredictable Trump Policy",
      "id": 133281246,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2185636755/image_2185636755.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Navigate market volatility with defensive stocks, bonds, and gold.",
      "url": "https://finnhub.io/api/news?id=3a7f34c516b912e4da5e6ab19d098a97e373f71f94dfa6f751a599d77a1b754c"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys",
    "summary": "February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.",
    "url": "https://finnhub.io/api/news?id=468f86fd4b412eee1971a4620667bbda7347c15c7444f076c7a1ef8f0edb1137",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1742463648,
      "headline": "My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 11 Buys",
      "id": 133276011,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "February investments fell below $1,000, mainly in BDCs like Owl Rock Capital and Ares Capital, boosting annual dividend income by $77.",
      "url": "https://finnhub.io/api/news?id=468f86fd4b412eee1971a4620667bbda7347c15c7444f076c7a1ef8f0edb1137"
    }
  }
]